Susceptibility of environmental versus clinical strains of pathogenic Aspergillus

被引:47
作者
Araujo, Ricardo
Pina-Vaz, Cidalia
Rodrigues, Acacio Goncalves
机构
[1] Univ Porto, Dept Microbiol, Fac Med, P-4200319 Oporto, Portugal
[2] Hosp Sao Joao, Dept Plast & Reconstruct Surg, Burn Unit, Oporto, Portugal
关键词
Aspergillus fumigatus; Aspergillus flavus; amphotericin B; itraconazole; voriconazole; caspofungin; susceptibility testing;
D O I
10.1016/j.ijantimicag.2006.09.019
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The objective of this study was to compare the antifungal susceptibility profiles of 307 environmental strains and 139 clinical isolates of Aspergillus belonging to six different species. Clinical and environmental strains with minimal inhibitory concentrations (MICs) or minimal effective concentrations >= 4 mu g/mL to amphotericin B (AMB), itraconazole (ITC), voriconazole and caspofungin were seldom detected. However, the susceptibility profile of environmental Aspergillus non-fumigatus strains suggests a native reduced susceptibility of Aspergillus flavus and Aspergillus terreus to AMB. A single environmental strain of Aspergillus nidulans showed high in vitro resistance (MIC >= 16 mu g/mL) to ITC. Aspergillus niger showed significantly higher MIC values to ITC compared with the other Aspergillus spp. Conversely, A. fumigatus and Aspergillus glaucus showed higher susceptible profiles to the antifungals. Definition of the breakpoints for the antifungal agents remains urgent. The relationship between the susceptibility pattern and the pathogenic potential also deserves more attention, particularly with regard to non-fumigatus species. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:108 / 111
页数:4
相关论文
共 15 条
[1]   In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247
[2]   Comparison of virulence between clinical and environmental isolates of Aspergillus fumigatus [J].
Aufauvre-Brown, A ;
Brown, JS ;
Holden, DW .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (11) :778-780
[3]   Acquired itraconazole resistance in Aspergillus fumigatus [J].
Dannaoui, E ;
Borel, E ;
Monier, MF ;
Piens, MA ;
Picot, S ;
Persat, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) :333-340
[4]  
Espinel-Ingroff Ana, 2003, Revista Iberoamericana de Micologia, V20, P121
[5]   Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples:: Analysis by site of isolation [J].
Guinea, J ;
Peláez, T ;
Alcalá, L ;
Ruiz-Serrano, MJ ;
Bouza, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3495-3497
[6]   Invasive pulmonary aspergillosis due to Aspergillus terreus:: 12-year experience and review of the literature [J].
Iwen, PC ;
Rupp, ME ;
Langnas, AN ;
Reed, EC ;
Hinrichs, SH .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (05) :1092-1097
[7]   In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis [J].
Lass-Flörl, C ;
Kofler, G ;
Kropshofer, G ;
Hermans, J ;
Kreczy, A ;
Dierich, MP ;
Niederwieser, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :497-502
[8]   Epidemiology and outcome of infections due to Aspergillus terreus:: 10-year single centre experience [J].
Lass-Flörl, C ;
Griff, K ;
Mayr, A ;
Petzer, A ;
Gastl, G ;
Bonatti, H ;
Freund, M ;
Kropshofer, G ;
Dierich, MP ;
Nachbaur, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :201-207
[9]   Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors [J].
Marr, KA ;
Carter, RA ;
Boeckh, M ;
Martin, P ;
Corey, L .
BLOOD, 2002, 100 (13) :4358-4366
[10]   Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates [J].
Meneau, I ;
Sanglard, D .
MEDICAL MYCOLOGY, 2005, 43 :S307-S311